{"id":2587,"date":"2021-05-03T21:00:21","date_gmt":"2021-05-03T12:00:21","guid":{"rendered":"https:\/\/plaza.umin.ac.jp\/~OIO\/?p=2587"},"modified":"2021-05-04T12:06:43","modified_gmt":"2021-05-04T03:06:43","slug":"pulmonary-hypertension-and-imatinib-or-nilotinib-or-dasatinib-filters-abstract-clinical-trial-observational-study-randomized-controlled-trial","status":"publish","type":"post","link":"https:\/\/plaza.umin.ac.jp\/~OIO\/?p=2587","title":{"rendered":"(pulmonary hypertension) AND ((imatinib) OR (nilotinib) OR (dasatinib)) Filters: Abstract, Clinical Trial, Observational Study, Randomized Controlled Trial"},"content":{"rendered":"
\n
\n\n\n\n\n\n
Sent by NCBI\u00a0<\/b><nobody@ncbi.nlm.nih.gov><\/span><\/td>\n2021\u5e745\u67083\u65e5 17:13<\/span><\/td>\n<\/tr>\n
<\/td>\n<\/tr>\n
\n\n\n\n
This message contains search results from the National Center for Biotechnology Information\u00a0<\/span>(NCBI)<\/a>\u00a0<\/span>at the U.S. National Library of Medicine\u00a0<\/span>(NLM)<\/a>. Do not reply directly to this message<\/p>\n

Sent On:<\/b>\u00a0<\/span>Mon May 03 04:13:00 2021<\/p>\n

Search:<\/b>\u00a0<\/span>(pulmonary hypertension) AND ((imatinib) OR (nilotinib) OR (dasatinib)) Filters: Abstract, Clinical Trial, Observational Study, Randomized Controlled Trial<\/p>\n

16 selected items<\/p>\n

PubMed Results<\/div>\n

Items 1-16 of 16 (Display the 16 citations in PubMed<\/a>)<\/p>\n

<\/u><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
1.<\/div>\n<\/td>\n
\n
\n

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension<\/a><\/h1>\n
J Clin Invest.\u00a02016 Sep 1;126(9):3207-18.<\/span>\u00a0doi: 10.1172\/JCI86249.\u00a0<\/span>Epub 2016 Aug 2.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Christophe Guignabert<\/a>,\u00a0<\/span>Carole Phan<\/a>,\u00a0<\/span>Andrei Seferian<\/a>,\u00a0<\/span>Alice Huertas<\/a>,\u00a0<\/span>Ly Tu<\/a>,\u00a0<\/span>Rapha\u00ebl Thuillet<\/a>,\u00a0<\/span>Caroline Sattler<\/a>,\u00a0<\/span>Morane Le Hiress<\/a>,\u00a0<\/span>Yuichi Tamura<\/a>,\u00a0<\/span>Etienne-Marie Jutant<\/a>,\u00a0<\/span>Marie-Camille Chaumais<\/a>,\u00a0<\/span>St\u00e9phane Bouchet<\/a>,\u00a0<\/span>Benjamin Man\u00e9glier<\/a>,\u00a0<\/span>Mathieu Molimard<\/a>,\u00a0<\/span>Philippe Rousselot<\/a>,\u00a0<\/span>Olivier Sitbon<\/a>,\u00a0<\/span>G\u00e9rald Simonneau<\/a>,\u00a0<\/span>David Montani<\/a>,\u00a0<\/span>Marc Humbert<\/a><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
2.<\/div>\n<\/td>\n
\n
\n

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034<\/a><\/h1>\n
Am J Hematol.\u00a02016 Sep;91(9):869-74.<\/span>\u00a0doi: 10.1002\/ajh.24423.\u00a0<\/span>Epub 2016 Jun 20.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Neil P Shah<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Philippe Rousselot<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Charles Schiffer<\/a>\u00a0\u00a03\u00a0<\/sup>,\u00a0<\/span>Delphine Rea<\/a>\u00a0\u00a04\u00a0<\/sup>,\u00a0<\/span>Jorge E Cortes<\/a>\u00a0\u00a05\u00a0<\/sup>,\u00a0<\/span>Jorge Milone<\/a>\u00a0\u00a06\u00a0<\/sup>,\u00a0<\/span>Hesham Mohamed<\/a>\u00a0\u00a07\u00a0<\/sup>,\u00a0<\/span>Diane Healey<\/a>\u00a0\u00a07\u00a0<\/sup>,\u00a0<\/span>Hagop Kantarjian<\/a>\u00a0\u00a05\u00a0<\/sup>,\u00a0<\/span>Andreas Hochhaus<\/a>\u00a0\u00a08\u00a0<\/sup>,\u00a0<\/span>Giuseppe Saglio<\/a> \u00a09<\/sup><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
3.<\/div>\n<\/td>\n
\n
\n

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial<\/a><\/h1>\n
J Clin Oncol.\u00a02018 May 1;36(13):1330-1338.<\/span>\u00a0doi: 10.1200\/JCO.2017.75.9597.\u00a0<\/span>Epub 2018 Mar 2.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Lia Gore<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Pamela R Kearns<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Maria Lucia de Martino<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Lee<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Carmino Antonio De Souza<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Yves Bertrand<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Nobuko Hijiya<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Linda C Stork<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Nack-Gyun Chung<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Rocio Cardenas Cardos<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Tapan Saikia<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Franca Fagioli<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Jong Jin Seo<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Judith Landman-Parker<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Donna Lancaster<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Andrew E Place<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Karen R Rabin<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Mariana Sacchi<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Rene Swanink<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>C Michel Zwaan<\/a> \u00a01<\/sup><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
4.<\/div>\n<\/td>\n
\n
\n

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial<\/a><\/h1>\n
Lancet Oncol.\u00a02020 Jul;21(7):923-934.<\/span>\u00a0doi: 10.1016\/S1470-2045(20)30168-6.\u00a0<\/span>Epub 2020 Jun 5.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Jean-Yves Blay<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>C\u00e9sar Serrano<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Michael C Heinrich<\/a>\u00a0\u00a03\u00a0<\/sup>,\u00a0<\/span>John Zalcberg<\/a>\u00a0\u00a04\u00a0<\/sup>,\u00a0<\/span>Sebastian Bauer<\/a>\u00a0\u00a05\u00a0<\/sup>,\u00a0<\/span>Hans Gelderblom<\/a>\u00a0\u00a06\u00a0<\/sup>,\u00a0<\/span>Patrick Sch\u00f6ffski<\/a>\u00a0\u00a07\u00a0<\/sup>,\u00a0<\/span>Robin L Jones<\/a>\u00a0\u00a08\u00a0<\/sup>,\u00a0<\/span>Steven Attia<\/a>\u00a0\u00a09\u00a0<\/sup>,\u00a0<\/span>Gina D’Amato<\/a>\u00a0\u00a010\u00a0<\/sup>,\u00a0<\/span>Ping Chi<\/a>\u00a0\u00a011\u00a0<\/sup>,\u00a0<\/span>Peter Reichardt<\/a>\u00a0\u00a012\u00a0<\/sup>,\u00a0<\/span>Julie Meade<\/a>\u00a0\u00a013\u00a0<\/sup>,\u00a0<\/span>Kelvin Shi<\/a>\u00a0\u00a013\u00a0<\/sup>,\u00a0<\/span>Rodrigo Ruiz-Soto<\/a>\u00a0\u00a013\u00a0<\/sup>,\u00a0<\/span>Suzanne George<\/a>\u00a0\u00a014\u00a0<\/sup>,\u00a0<\/span>Margaret von Mehren<\/a>\u00a0\u00a015<\/sup><\/span><\/div>\n<\/div>\n
<\/div>\n<\/div>\n<\/div>\n

\n
5.<\/div>\n<\/td>\n
\n
\n
\n

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study<\/a><\/h1>\n
Circulation.\u00a02013 Mar 12;127(10):1128-38.<\/span>\u00a0doi: 10.1161\/CIRCULATIONAHA.112.000765.\u00a0<\/span>Epub 2013 Feb 12.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Marius M Hoeper<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Robyn J Barst<\/a>,\u00a0<\/span>Robert C Bourge<\/a>,\u00a0<\/span>Jeremy Feldman<\/a>,\u00a0<\/span>Adaani E Frost<\/a>,\u00a0<\/span>Nazzareno Gali\u00e9<\/a>,\u00a0<\/span>Miguel Angel G\u00f3mez-S\u00e1nchez<\/a>,\u00a0<\/span>Friedrich Grimminger<\/a>,\u00a0<\/span>Ekkehard Gr\u00fcnig<\/a>,\u00a0<\/span>Paul M Hassoun<\/a>,\u00a0<\/span>Nicholas W Morrell<\/a>,\u00a0<\/span>Andrew J Peacock<\/a>,\u00a0<\/span>Toru Satoh<\/a>,\u00a0<\/span>G\u00e9rald Simonneau<\/a>,\u00a0<\/span>Victor F Tapson<\/a>,\u00a0<\/span>Fernando Torres<\/a>,\u00a0<\/span>David Lawrence<\/a>,\u00a0<\/span>Deborah A Quinn<\/a>,\u00a0<\/span>Hossein-Ardeschir Ghofrani<\/a><\/span><\/div>\n<\/div>\n
<\/div>\n<\/div>\n<\/div>\n<\/header>\n
\n

Abstract<\/h2>\n
\n

\u80cc\u666f\u00a0\u8840\u5c0f\u677f\u7531\u6765\u6210\u9577\u56e0\u5b50\u30b7\u30b0\u30ca\u30eb\u306e\u963b\u5bb3\u4f5c\u7528\u306b\u3088\u308a\u3001\u30a4\u30de\u30c1\u30cb\u30d6\u306f\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\uff08PAH\uff09\u60a3\u8005\u306e\u6cbb\u7642\u306b\u6709\u52b9\u306a\u53ef\u80fd\u6027\u304c\u3042\u308b\u3002<\/span><\/p>\n

\u65b9\u6cd5\u3068\u7d50\u679c\u00a0Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)\u306f\u300124\u9031\u9593\u306e\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u8a66\u9a13\u3067\u30012\u7a2e\u985e\u4ee5\u4e0a\u306ePAH\u6cbb\u7642\u3092\u53d7\u3051\u3066\u3044\u308b\u75c7\u72b6\u306e\u3042\u308b\u80ba\u8840\u7ba1\u62b5\u6297800 dyne-s-cm(-5)\u4ee5\u4e0a\u306e\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u30a4\u30de\u30c1\u30cb\u30d6\u3092\u8a55\u4fa1\u3057\u305f\u3002\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u306f\u30016\u5206\u9593\u306e\u6b69\u884c\u8ddd\u96e2\u306e\u5909\u5316\u3067\u3057\u305f\u3002\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u306f\u3001\u8840\u884c\u52d5\u614b\u3001\u6a5f\u80fd\u30af\u30e9\u30b9\u3001N\u672b\u7aef\u8133\u6027\u30ca\u30c8\u30ea\u30a6\u30e0\u5229\u5c3f\u30da\u30d7\u30c1\u30c9\u306e\u8840\u6e05\u30ec\u30d9\u30eb\u3001\u81e8\u5e8a\u7684\u60aa\u5316\u307e\u3067\u306e\u671f\u9593\u306e\u5909\u5316\u3067\u3057\u305f\u3002\u30b3\u30a2\u8a66\u9a13\u7d42\u4e86\u5f8c\u3001\u60a3\u8005\u306f\u975e\u76f2\u691c\u306e\u9577\u671f\u5ef6\u9577\u8a66\u9a13\u306b\u53c2\u52a0\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u305f\u3002\u767b\u9332\u3055\u308c\u305f202\u540d\u306e\u60a3\u8005\u306e\u3046\u3061\u300141\uff05\u306e\u60a3\u8005\u304c3\u7a2e\u985e\u306ePAH\u6cbb\u7642\u3092\u53d7\u3051\u3001\u6b8b\u308a\u306e\u60a3\u8005\u306f2\u7a2e\u985e\u306e\u6cbb\u7642\u3092\u53d7\u3051\u307e\u3057\u305f\u300224\u9031\u5f8c\u306e6\u5206\u9593\u6b69\u884c\u8ddd\u96e2\u306b\u5bfe\u3059\u308b\u30d7\u30e9\u30bb\u30dc\u88dc\u6b63\u5f8c\u306e\u6cbb\u7642\u52b9\u679c\u306f\u5e73\u574732m\uff0895\uff05\u4fe1\u983c\u533a\u9593\u300112\uff5e52\u3001P=0.002\uff09\u3067\u3001\u5ef6\u9577\u8a66\u9a13\u3067\u3082\u30a4\u30de\u30c1\u30cb\u30d6\u3092\u7d99\u7d9a\u6295\u4e0e\u3057\u305f\u60a3\u8005\u3067\u306f\u52b9\u679c\u304c\u7dad\u6301\u3055\u308c\u305f\u3002\u80ba\u8840\u7ba1\u62b5\u6297\u306f 379 dyne-s-cm(-5) \u6e1b\u5c11\u3057\u305f\uff0895%\u4fe1\u983c\u533a\u9593\uff1a-502\uff5e-255\uff1bP<0.001\u3001\u7fa4\u9593\u5dee\uff09\u3002\u6a5f\u80fd\u30af\u30e9\u30b9\uff0c\u81e8\u5e8a\u7684\u60aa\u5316\u307e\u3067\u306e\u671f\u9593\uff0c\u6b7b\u4ea1\u7387\u306f\u6cbb\u7642\u6cd5\u9593\u3067\u5dee\u304c\u306a\u304b\u3063\u305f\uff0e<\/span>\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u304a\u3088\u3073\u6295\u4e0e\u4e2d\u6b62\u306f\uff0c\u30a4\u30de\u30c1\u30cb\u30d6\u306e\u65b9\u304c\u30d7\u30e9\u30bb\u30dc\u3088\u308a\u3082\u591a\u304b\u3063\u305f\uff08\u305d\u308c\u305e\u308c44\uff05\u5bfe30\uff05\uff0c33\uff05\u5bfe18\uff05\uff09\uff0e\u786c\u819c\u4e0b\u8840\u816b\u306f\u3001\u30a4\u30de\u30c1\u30cb\u30d6\u3068\u6297\u51dd\u56fa\u7642\u6cd5\u3092\u53d7\u3051\u305f 8 \u540d\u306e\u60a3\u8005\uff08\u4e2d\u6838\u8a66\u9a13\u3067 2 \u540d\u3001\u5ef6\u9577\u8a66\u9a13\u3067 6 \u540d\uff09\u306b\u767a\u751f\u3057\u307e\u3057\u305f\u3002<\/p>\n

\u7d50\u8ad6\u3068\u3057\u3066\u306f\u00a0\u30a4\u30de\u30c1\u30cb\u30d6\u306f\uff0c\u9032\u884c\u3057\u305fPAH\u60a3\u8005\u306e\u904b\u52d5\u80fd\u529b\u3068\u8840\u884c\u52d5\u614b\u3092\u6539\u5584\u3057\u305f\u304c\uff0c\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u3068\u8a66\u9a13\u85ac\u306e\u4e2d\u6b62\u304c\u591a\u304b\u3063\u305f<\/span>\u3002PAH \u60a3\u8005\u306b\u304a\u3051\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u306e\u9577\u671f\u7684\u306a\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u3092\u691c\u8a0e\u3059\u308b\u305f\u3081\u306b\u306f\uff0c\u3055\u3089\u306a\u308b\u7814\u7a76\u304c\u5fc5\u8981\u3067\u3042\u308b<\/p>\n

Clinical trial registration:\u00a0<\/span><\/strong>URL:\u00a0<\/span>http:\/\/www.clinicaltrials.gov<\/a>. Unique identifier:\u00a0<\/span>NCT00902174<\/a>\u00a0<\/span>(core study);\u00a0<\/span>NCT01392495<\/a>\u00a0<\/span>(extension).<\/p>\n<\/div>\n<\/div>\n

\n
6.<\/div>\n<\/td>\n
\n
\n
\n

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension<\/a><\/h1>\n
J Heart Lung Transplant.\u00a02015 Nov;34(11):1366-75.<\/span>\u00a0doi: 10.1016\/j.healun.2015.05.025.\u00a0<\/span>Epub 2015 Jun 11.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Adaani E Frost<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Robyn J Barst<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Marius M Hoeper<\/a>\u00a0\u00a03\u00a0<\/sup>,\u00a0<\/span>Hyuk-Jae Chang<\/a>\u00a0\u00a04\u00a0<\/sup>,\u00a0<\/span>Robert P Frantz<\/a>\u00a0\u00a05\u00a0<\/sup>,\u00a0<\/span>Yoshihiro Fukumoto<\/a>\u00a0\u00a06\u00a0<\/sup>,\u00a0<\/span>Nazzareno Gali\u00e9<\/a>\u00a0\u00a07\u00a0<\/sup>,\u00a0<\/span>Paul M Hassoun<\/a>\u00a0\u00a08\u00a0<\/sup>,\u00a0<\/span>Hans Klose<\/a>\u00a0\u00a09\u00a0<\/sup>,\u00a0<\/span>Hiromi Matsubara<\/a>\u00a0\u00a010\u00a0<\/sup>,\u00a0<\/span>Nicholas W Morrell<\/a>\u00a0\u00a011\u00a0<\/sup>,\u00a0<\/span>Andrew J Peacock<\/a>\u00a0\u00a012\u00a0<\/sup>,\u00a0<\/span>Michael Pfeifer<\/a>\u00a0\u00a013\u00a0<\/sup>,\u00a0<\/span>G\u00e9rald Simonneau<\/a>\u00a0\u00a014\u00a0<\/sup>,\u00a0<\/span>Victor F Tapson<\/a>\u00a0\u00a015\u00a0<\/sup>,\u00a0<\/span>Fernando Torres<\/a>\u00a0\u00a016\u00a0<\/sup>,\u00a0<\/span>Carmine Dario Vizza<\/a>\u00a0\u00a017\u00a0<\/sup>,\u00a0<\/span>David Lawrence<\/a>\u00a0\u00a018\u00a0<\/sup>,\u00a0<\/span>Wei Yang<\/a>\u00a0\u00a018\u00a0<\/sup>,\u00a0<\/span>James M Felser<\/a>\u00a0\u00a018\u00a0<\/sup>,\u00a0<\/span>Deborah A Quinn<\/a>\u00a0\u00a018\u00a0<\/sup>,\u00a0<\/span>Hossein-Ardeschir Ghofrani<\/a> \u00a019<\/sup><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/header>\n
\n

Abstract<\/h2>\n
\n

\u80cc\u666f\u00a0\u30a4\u30de\u30c1\u30cb\u30d6\u306f\u3001\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u75c5\u614b\u751f\u7406\u306b\u95a2\u4e0e\u3059\u308b\u8907\u6570\u306e\u30d7\u30ed\u30c6\u30a4\u30f3\u30ad\u30ca\u30fc\u30bc\u3092\u963b\u5bb3\u3059\u308b<\/span>\u7d4c\u53e3\u85ac\u3067\u3042\u308b\u3002\u30a4\u30de\u30c1\u30cb\u30d6\u3092\u6295\u4e0e\u3057\u305f\u3068\u3053\u308d\u30012\u301c3\u7a2e\u985e\u306ePAH\u7279\u7570\u7684\u6cbb\u7642\u6cd5\u306b\u53cd\u5fdc\u3057\u306a\u3044\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u5bfe\u7167\u8a66\u9a13\uff08Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized Efficacy Study [IMPRES]\uff09\u306b\u304a\u3044\u3066\u3001\u8840\u884c\u52d5\u614b\u3068\u904b\u52d5\u80fd\u529b\u306e\u6539\u5584\u304c\u8a8d\u3081\u3089\u308c\u305f\u3002<\/p>\n

\u65b9\u6cd5\u3067\u3059\u3002\u00a0\u3053\u306e\u975e\u76f2\u691c\u5ef6\u9577\u8a66\u9a13\u306b\u304a\u3051\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u306e\u9577\u671f\uff08204\u9031\u307e\u3067\uff09\u306e\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u306b\u3064\u3044\u3066\u30012014\u5e744\u670816\u65e5\u306e\u65e9\u671f\u8a66\u9a13\u7d42\u4e86\u307e\u3067\u691c\u8a0e\u3057\u305f\u3002IMPRES\u306b\u767b\u9332\u3055\u308c\u305f202\u540d\u306e\u60a3\u8005\u306e\u3046\u3061\u300166\u540d\u306e\u30a4\u30de\u30c1\u30cb\u30d6\u6295\u4e0e\u8005\u306878\u540d\u306e\u30d7\u30e9\u30bb\u30dc\u6295\u4e0e\u8005\u304c\u5ef6\u9577\u8a66\u9a13\u306b\u53c2\u52a0\u3057\u307e\u3057\u305f\u3002<\/p>\n

\u7d50\u679c\u00a0\u5168\u4f53\u3068\u3057\u3066\u300193.8\uff05\uff08144\u4eba\u4e2d135\u4eba\uff09\u306e\u60a3\u8005\u304c\u5ef6\u9577\u8a66\u9a13\u3092\u4e2d\u6b62\u3057\u305f\u3002\u4e2d\u6b62\u306e\u4e3b\u306a\u7406\u7531\u306f\u3001\u7ba1\u7406\u4e0a\u306e\u554f\u984c\uff08\u3059\u306a\u308f\u3061\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u306e\u7d42\u4e86\uff1b32.6\uff05\uff09\u3068\u6709\u5bb3\u4e8b\u8c61\uff0831.3\uff05\uff09\u3067\u3042\u3063\u305f\u3002\u5ef6\u9577\u8a66\u9a13\u304c\u7d42\u4e86\u3059\u308b\u307e\u3067\u306b9\u540d\u306e\u60a3\u8005\u304c\u5ef6\u9577\u8a66\u9a13\u3092\u5b8c\u4e86\u3057\u305f\u3002\u91cd\u7be4\u3067\u4e88\u671f\u305b\u306c\u6709\u5bb3\u4e8b\u8c61\u304c\u983b\u767a\u3057\u305f\u3002\u5ef6\u9577\u8a66\u9a13\u3067\u306f\u786c\u819c\u4e0b\u8840\u816b\u304c6\u4f8b\u3001\u8a66\u9a13\u4e2d\u307e\u305f\u306f\u8a66\u9a13\u7d42\u4e86\u5f8c30\u65e5\u4ee5\u5185\u306b\u6b7b\u4ea1\u3057\u305f\u306e\u306f17\u4f8b\u3067\u3042\u3063\u305f\u3002\u30a4\u30de\u30c1\u30cb\u30d6\u306b\u8010\u3048\u3001\u5ef6\u9577\u8a66\u9a13\u3092\u3088\u308a\u9577\u304f\u7d9a\u3051\u305f\u60a3\u8005\u306f\u3001\u6a5f\u80fd\u30af\u30e9\u30b9\u3068\u6b69\u884c\u8ddd\u96e2\u306e\u6539\u5584\u3092\u7d4c\u9a13\u3057\u305f\u304c\u3001\u307b\u3068\u3093\u3069\u306e\u60a3\u8005\u306f\u85ac\u5264\u3068\u8a66\u9a13\u3092\u4e2d\u6b62\u3057\u305f\u3002<\/span><\/p>\n

\u7d50\u8ad6\u3068\u3057\u3066\u306f\u00a0\u91cd\u5ea6\u306e\u6709\u5bb3\u4e8b\u8c61\u3001\u91cd\u5927\u306a\u526f\u4f5c\u7528\u3001\u305d\u3057\u3066\u9ad8\u3044\u6295\u4e0e\u4e2d\u6b62\u7387\u306f\u3001PAH\u6cbb\u7642\u306b\u304a\u3051\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u306e\u6709\u7528\u6027\u3092\u5236\u9650\u3059\u308b\u3002\u3053\u308c\u3089\u306e\u30ea\u30b9\u30af\u306f\u3001\u6295\u4e0e\u3092\u7d99\u7d9a\u3067\u304d\u305f\u60a3\u8005\u306b\u898b\u3089\u308c\u305f\u8840\u884c\u52d5\u614b\u3084\u6b69\u884c\u8ddd\u96e2\u306e\u6539\u5584\u3092\u4e0a\u56de\u308b\u3082\u306e\u3067\u3042\u308b\u3002PAH \u306b\u5bfe\u3059\u308b\u30a4\u30de\u30c1\u30cb\u30d6\u306e\u9069\u5fdc\u5916\u4f7f\u7528\u306f\u304a\u52e7\u3081\u3057\u307e\u305b\u3093<\/span>\u3002<\/p>\n<\/div>\n

Trial registration:\u00a0<\/span><\/strong>ClinicalTrials.gov\u00a0<\/span>NCT01392495<\/a>.<\/p>\n

Keywords:\u00a0<\/span><\/strong>efficacy; imatinib; long-term; pulmonary arterial hypertension; safety.<\/p>\n<\/div>\n

Copyright \u00a9 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.<\/p>\n

\n
7.<\/div>\n<\/td>\n
\n
\n
\n

Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension<\/a><\/h1>\n
Respiration.\u00a02015;89(6):515-24.<\/span>\u00a0doi: 10.1159\/000381923.\u00a0<\/span>Epub 2015 Jun 3.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Rudolf Speich<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Silvia Ulrich<\/a>,\u00a0<\/span>Guido Domenighetti<\/a>,\u00a0<\/span>Lars C Huber<\/a>,\u00a0<\/span>Manuel Fischler<\/a>,\u00a0<\/span>Ursula Treder<\/a>,\u00a0<\/span>Alexander Breitenstein<\/a><\/span><\/div>\n<\/div>\n
\n

 <\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
8.<\/div>\n<\/td>\n
\n
\n
\n

Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension<\/a><\/h1>\n
Br J Clin Pharmacol.\u00a02015 Jul;80(1):75-85.<\/span>\u00a0doi: 10.1111\/bcp.12584.\u00a0<\/span>Epub 2015 Jun 1.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Didier Renard<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Thomas Bouillon<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Ping Zhou<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Gerard Flesch<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Debbie Quinn<\/a> \u00a03<\/sup><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
9.<\/div>\n<\/td>\n
\n
\n
\n

Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis<\/a><\/h1>\n
Respir Med.\u00a02017 Oct;131:215-219.<\/span>\u00a0doi: 10.1016\/j.rmed.2017.08.032.\u00a0<\/span>Epub 2017 Sep 12.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Aiko Ogawa<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Katsumasa Miyaji<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Hiromi Matsubara<\/a> \u00a03<\/sup><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
10.<\/div>\n<\/td>\n
\n
\n
\n

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy<\/a><\/h1>\n
Am J Respir Crit Care Med.\u00a02010 Nov 1;182(9):1171-7.<\/span>\u00a0doi: 10.1164\/rccm.201001-0123OC.\u00a0<\/span>Epub 2010 Jun 25.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Hossein A Ghofrani<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Nicholas W Morrell<\/a>,\u00a0<\/span>Marius M Hoeper<\/a>,\u00a0<\/span>Horst Olschewski<\/a>,\u00a0<\/span>Andrew J Peacock<\/a>,\u00a0<\/span>Robyn J Barst<\/a>,\u00a0<\/span>Shelley Shapiro<\/a>,\u00a0<\/span>Heiko Golpon<\/a>,\u00a0<\/span>Mark Toshner<\/a>,\u00a0<\/span>Friedrich Grimminger<\/a>,\u00a0<\/span>Steve Pascoe<\/a><\/span><\/div>\n<\/div>\n
\n

Affiliation<\/a><\/h3>\n<\/div>\n<\/div>\n<\/div>\n

\n
11.<\/div>\n<\/td>\n
\n
\n
\n

Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension<\/a><\/h1>\n
Eur J Heart Fail.\u00a02015 Jan;17(1):63-73.<\/span>\u00a0doi: 10.1002\/ejhf.177.\u00a0<\/span>Epub 2014 Nov 4.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Gabriela Querejeta Roca<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Patricia Campbell<\/a>,\u00a0<\/span>Brian Claggett<\/a>,\u00a0<\/span>Ali Vazir<\/a>,\u00a0<\/span>Debbie Quinn<\/a>,\u00a0<\/span>Scott D Solomon<\/a>,\u00a0<\/span>Amil M Shah<\/a><\/span><\/div>\n<\/div>\n
\n

Affiliation<\/h3>\n

\n
12.<\/div>\n<\/td>\n
\n
\n
\n

Right Atrial Function in Pulmonary Arterial Hypertension<\/a><\/h1>\n
Circ Cardiovasc Imaging.\u00a02015 Nov;8(11):e003521; discussion e003521.<\/span>\u00a0doi: 10.1161\/CIRCIMAGING.115.003521.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Gabriela Querejeta Roca<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Patricia Campbell<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Brian Claggett<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Scott D Solomon<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Amil M Shah<\/a> \u00a02<\/sup><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
13.<\/div>\n<\/td>\n
\n
\n

Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension<\/a><\/h1>\n
Int Heart J.\u00a02010 Jul;51(4):272-6.<\/span>\u00a0doi: 10.1536\/ihj.51.272.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Masaru Hatano<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Atsushi Yao<\/a>,\u00a0<\/span>Taro Shiga<\/a>,\u00a0<\/span>Koichiro Kinugawa<\/a>,\u00a0<\/span>Yasunobu Hirata<\/a>,\u00a0<\/span>Ryozo Nagai<\/a><\/span><\/div>\n<\/div>\n
<\/div>\n<\/div>\n<\/div>\n

\n
14.<\/div>\n<\/td>\n
\n
\n
\n

Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension<\/a><\/h1>\n
Eur Heart J.\u00a02015 Mar 7;36(10):623-32.<\/span>\u00a0doi: 10.1093\/eurheartj\/ehu035.\u00a0<\/span>Epub 2014 Feb 23.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Amil M Shah<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Patricia Campbell<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Gabriela Querejeta Rocha<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Andrew Peacock<\/a>\u00a0\u00a03\u00a0<\/sup>,\u00a0<\/span>Robyn J Barst<\/a>\u00a0\u00a04\u00a0<\/sup>,\u00a0<\/span>Debbie Quinn<\/a>\u00a0\u00a05\u00a0<\/sup>,\u00a0<\/span>Scott D Solomon<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>IMPRES Investigators<\/a><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
15.<\/div>\n<\/td>\n
\n
\n
\n

Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments<\/a><\/h1>\n
Circulation.\u00a02013 Sep 10;128(11):1214-24.<\/span>\u00a0doi: 10.1161\/CIRCULATIONAHA.113.004136.\u00a0<\/span>Epub 2013 Jul 30.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Lan Zhao<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Ali Ashek<\/a>,\u00a0<\/span>Lei Wang<\/a>,\u00a0<\/span>Wei Fang<\/a>,\u00a0<\/span>Swati Dabral<\/a>,\u00a0<\/span>Olivier Dubois<\/a>,\u00a0<\/span>John Cupitt<\/a>,\u00a0<\/span>Soni Savai Pullamsetti<\/a>,\u00a0<\/span>Emanuele Cotroneo<\/a>,\u00a0<\/span>Hazel Jones<\/a>,\u00a0<\/span>Gianpaolo Tomasi<\/a>,\u00a0<\/span>Quang-De Nguyen<\/a>,\u00a0<\/span>Eric O Aboagye<\/a>,\u00a0<\/span>Mona A El-Bahrawy<\/a>,\u00a0<\/span>Gareth Barnes<\/a>,\u00a0<\/span>Luke S Howard<\/a>,\u00a0<\/span>J Simon R Gibbs<\/a>,\u00a0<\/span>Willy Gsell<\/a>,\u00a0<\/span>Jian-Guo He<\/a>,\u00a0<\/span>Martin R Wilkins<\/a><\/span><\/div>\n<\/div>\n
<\/div>\n<\/div>\n<\/div>\n

\n
16.<\/div>\n<\/td>\n
\n
\n
\n

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial<\/a><\/h1>\n
Lancet Oncol.\u00a02016 May;17(5):632-41.<\/span>\u00a0doi: 10.1016\/S1470-2045(16)00075-9.\u00a0<\/span>Epub 2016 Apr 5.<\/span><\/div>\n
\n
\n
\n

Authors<\/h3>\n
Olivier Mir<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Claire Cropet<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Maud Toulmonde<\/a>\u00a0\u00a03\u00a0<\/sup>,\u00a0<\/span>Axel Le Cesne<\/a>\u00a0\u00a01\u00a0<\/sup>,\u00a0<\/span>Mathieu Molimard<\/a>\u00a0\u00a04\u00a0<\/sup>,\u00a0<\/span>Emmanuelle Bompas<\/a>\u00a0\u00a05\u00a0<\/sup>,\u00a0<\/span>Philippe Cassier<\/a>\u00a0\u00a06\u00a0<\/sup>,\u00a0<\/span>Isabelle Ray-Coquard<\/a>\u00a0\u00a06\u00a0<\/sup>,\u00a0<\/span>Maria Rios<\/a>\u00a0\u00a07\u00a0<\/sup>,\u00a0<\/span>Antoine Adenis<\/a>\u00a0\u00a08\u00a0<\/sup>,\u00a0<\/span>Antoine Italiano<\/a>\u00a0\u00a03\u00a0<\/sup>,\u00a0<\/span>Olivier Bouch\u00e9<\/a>\u00a0\u00a09\u00a0<\/sup>,\u00a0<\/span>Emmanuelle Chauzit<\/a>\u00a0\u00a04\u00a0<\/sup>,\u00a0<\/span>Florence Duffaud<\/a>\u00a0\u00a010\u00a0<\/sup>,\u00a0<\/span>Fran\u00e7ois Bertucci<\/a>\u00a0\u00a011\u00a0<\/sup>,\u00a0<\/span>Nicolas Isambert<\/a>\u00a0\u00a012\u00a0<\/sup>,\u00a0<\/span>Julien Gautier<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>Jean-Yves Blay<\/a>\u00a0\u00a013\u00a0<\/sup>,\u00a0<\/span>David P\u00e9rol<\/a>\u00a0\u00a02\u00a0<\/sup>,\u00a0<\/span>PAZOGIST study group of the French Sarcoma Groupe-Groupe d’Etude des Tumeurs Osseuses (GSF-GETO)<\/a><\/span><\/div>\n<\/div>\n
<\/div>\n<\/div>\n<\/div>\n